Randomized phase 3 study of tarlatamab, a DLL3-targeting bispecific T-cell engager (BiTE), compared to standard of care in patients with relapsed small cell lung cancer (DeLLphi-304)
Authors
Paz-Ares, L. G.Felip, E.
Ahn, M. J.
Blackhall, Fiona H
Borghaei, H.
Cho, B. C.
Johnson, M. L.
Ramalingam, S. S.
Reck, M.
Zhang, A.
Ju, C. H.
Minocha, M.
Mukherjee, S.
Suri, G.
Jandial, D.
Bebb, D. G.
Affiliation
Hospital Universitario 12 de Octubre, CNIO-H120 Lung Cancer Unit, Ciberonc and Universidad Complutense, Madrid, SpainIssue Date
2023
Metadata
Show full item recordCitation
Paz-Ares LG, Felip E, Ahn MJ, Blackhall FH, Borghaei H, Cho BC, et al. Randomized phase 3 study of tarlatamab, a DLL3-targeting bispecific T-cell engager (BiTE), compared to standard of care in patients with relapsed small cell lung cancer (DeLLphi-304). Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772005482.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2023.41.16_suppl.TPS8611Additional Links
https://dx.doi.org/10.1200/JCO.2023.41.16_suppl.TPS8611Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.2023.41.16_suppl.TPS8611